跳到正文
原文
Medical Xpress·· 18 天前AI 评分54

人类登革热试验揭示免疫记忆如何帮助或反噬

Human dengue trial reveals how immune memory can help—or backfire

AI 导读

一项登革热病毒的人体挑战试验发现,免疫记忆在二次感染中可能增强病毒复制,导致更严重的疾病,但也可能提供持久的保护。适度的病毒复制与早期平衡的免疫反应相结合,提供了最强的保护。

正文
Dengue study reveals when immune memory helps protect against infection and when it backfires
Antibodies that most strongly enhanced dengue infection predicted the highest virus levels and delayed early antiviral responses, but that protection quickly waned. Credit: Pexels.

Spread through the bite of Aedes mosquitoes, dengue is a viral infection that can cause anything from mild fever, flu-like symptoms and joint pain to a severe form known as dengue hemorrhagic fever. What makes dengue particularly unusual and dangerous is that a second infection with a different strain, or serotype, can sometimes lead to more severe disease rather than stronger immunity.

A person's immune history can determine the fate of a second infection; some antibodies trigger an immune response that protects against the disease, while others can make it worse.

In a recent study published in Science Translational Medicine, researchers investigated how a person's past immune history changes the way their body reacts when infected with the dengue virus. They set up a human challenge study, a type of controlled clinical trial in which healthy adults were safely exposed to a weakened dengue virus, and a team tracked their immune reactions at every step.

Scientists had long assumed that the more a virus replicates and the better the immune system's initial attack, the stronger the protection. This trial showed the opposite. It found that excessive antibody-driven viral growth exhausted the immune system, leaving the defenses up only for a short while.

The researchers observed that balance was the key: Cases where moderate viral replication was coupled with early and balanced immune control provided the strongest and most durable immunity.

Familiarity breeds contempt

Dengue, caused by the dengue virus (DENV), infects nearly 100–400 million people each year, with about half of the world's population at risk. For this disease, catching it the second time is far more dangerous than catching it the first time.

Past infections leave behind antibodies that become part of the immune system's memory. For most viruses, these antibodies help protect you against future infections, but it's not so straightforward for dengue. DENV has four different strains (serotypes 1 through 4), and if you recover from one strain and later get infected with a different strain, your leftover antibodies may not be strong enough to neutralize the new strain.

Instead, the antibodies bind to the virus and accidentally help it enter immune cells more easily through a process called antibody-dependent enhancement. This can make the infection more powerful by pushing the virus to multiply faster and trigger severe, life-threatening complications like internal bleeding and fluid leakage.

This phenomenon makes vaccine development harder because an imperfect vaccine can mimic a first infection, and if the vaccinated person is later exposed to a natural strain, it may unintentionally raise their risk of enhanced, severe disease. To design better dengue therapeutics, scientists needed to identify how preexisting immunity and dengue antibodies shape the course of a second infection.

To find an answer, researchers designed a Phase I controlled human infection clinical trial conducted at the National Institutes of Health (NIH) Clinical Center in Maryland, U.S. They enrolled 45 healthy adults ages 18 to 59 and grouped them based on neutralizing antibodies in their blood at baseline (day 0) and their medical history. The groups were: no prior exposure to dengue; a single past natural infection with either DENV1, DENV2 or DENV4; and evidence of multiple past dengue infections.

Dengue study reveals when immune memory helps protect against infection and when it backfires
Final enrolled groups per day 0 neutralizing antibody titers are depicted with sample collection time points. Credit: Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.aei5117

Every volunteer received a single injection of a weakened DENV3 vaccine candidate in the upper arm. Participants were monitored closely for safety, daily symptoms and adverse reactions over 28 days. After this period, blood samples were collected on a precise longitudinal schedule from days 0 to 365 to study differences in viral load and clinical biomarkers.

More is not always merrier

Volunteers with one previous dengue infection had significantly higher peak viral loads than those never infected, driven by antibody-dependent enhancement (ADE). Those whose baseline antibodies most boosted viral replication showed delayed antiviral responses, followed by widespread inflammation. However, the early protection didn't last long, as these participants later experienced faster antibody decline and weaker sustained T-cell responses.

In contrast, volunteers with moderate viral replication mounted early antiviral responses and developed the most potent, long-lasting neutralizing antibodies against mature viruses across all four dengue serotypes. They also had the highest levels of protective memory from CD8-bearing T cells, which persisted for up to a year.

Dengue study reveals when immune memory helps protect against infection and when it backfires
The intermediate viremia group had the largest DENV-specific IFN-γ+ CD8+ T-cell responses at day 90. Credit: Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.aei5117

The experiments also revealed that antibodies targeting NS1, a viral protein that is not part of the virus's outer shell, across multiple dengue serotypes were linked to earlier, more balanced immune activation and better control of the virus.

The researchers showed that controlled dengue challenges in humans can distinguish well-coordinated immune responses from dysregulated ones and reveal how each affects the body's ability to build immunity. Lessons from such studies can help fine-tune treatments and vaccines for dengue and other viral diseases.

Written for you by our author Sanjukta Mondal, edited by Sadie Harley, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You'll get an ad-free account as a thank-you.

Publication details

Camila D. Odio et al., Dengue virus controlled human challenge reveals that preexisting immunity shapes viral replication and broadly protective responses, Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.aei5117

Journal information: Science Translational Medicine

Who's behind this story?

Sanjukta Mondal

Sanjukta Mondal

Master's in Chemistry. Freelance science journalist and communicator. Published in Chemistry World, BioSpace, and The Hindu. Full profile →

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

© 2026 Science X Network

Citation: Human dengue trial reveals how immune memory can help—or backfire (2026, November 2) retrieved 2 November 2026 from https://medicalxpress.com/news/2026-11-human-dengue-trial-reveals-immune.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com